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Abstract
Background: For many patients with aorto-occlusive disease, where stent deployment is not
possible, surgery remains the only treatment option available. The aim of this study was to assess
the results of aortic reconstruction surgery performed in patients with critical ischaemia.
Methods: All patients with critical ischaemia undergoing surgery during 1991–2004 were identified
from a prospectively maintained database. Mortality data was verified against death certificate data.
Demographic and clinical data were obtained from the clinical notes and the radiology database.
Disease was classified as: type I – limited to aorta and common iliac arteries; type II – external iliac
disease and type III combined aortic, iliac and infra-inguinal disease.
Results: 86 patients underwent aortic replacement surgery all of whom had critical ischaemia
consisting of: type I (n = 16); type II (n = 37) and type III (n = 33). The 30-day mortality rate was
10.4%, the one-year patient survival was 80%, and the 1-year graft survival was 80%. At 2 years the
actual patient survival was 73% and no additional graft losses were identified. All patients surviving
30 days reported excellent symptomatic relief. Early, complications occurred in 6 (7%) patients:
thrombosis within diseased superficial femoral arteries (n = 4); haemorrhage and subsequent death
(n = 2). Ten (14%) late complications (> 12 months) occurred in the 69 surviving patients and
included: anastomotic stenosis (n = 3); graft thrombosis (n = 4), graft infection (n = 3). Four patients
developed claudication as a result of more distal disease in the presence of a patent graft, and 1
patient who continued smoking required an amputation for progressive distal disease.
Conclusion: Aortic reconstruction for patients with extensive aorto-occlussive disease provides
long-standing symptomatic relief for the majority of patients. After the first year, there is continued
patient attrition due to co-existent cardiovascular disease but no further graft losses.
Published: 31 October 2008
BMC Surgery 2008, 8:19 doi:10.1186/1471-2482-8-19
Received: 1 November 2007
Accepted: 31 October 2008
This article is available from: http://www.biomedcentral.com/1471-2482/8/19
© 2008 Morris-Stiff et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Surgery 2008, 8:19 http://www.biomedcentral.com/1471-2482/8/19
Page 2 of 6
(page number not for citation purposes)
Background
The infra-renal abdominal aorta and iliac arteries are
amongst the commonest sites for symptomatic stenotic
atherosclerotic lesions [1]. Stenoses are most commonly
identified in related to arterial bifurcation; of the aorta
into common iliac arteries, and common into internal
and external iliac vessels.
Aorto-occlussive diseases (AOD) may be classified into 3
subtypes: I – stenoses within the aorta and common iliacs;
II – stenoses extending into the external iliac arteries; III –
stenoses within the aorta, iliac vessels and common fem-
oral arteries [2]. The typical distribution of AOD, as
reported in the literature, is type III (65%) followed by
type II (25%) and type I (10%). Patients with type I AOD
are frequently asymptomatic due to the development of a
network of collaterals, however, they can develop claudi-
cation within the proximal musculature of the buttock
and thigh [3]. Type II AOD usually presents with buttock
and thigh claudication whilst patients with type III disease
typically present with intermittent claudication.
The development of balloon technology allowing percu-
taneous angioplasty and vascular stenting has meant that
many patients with focal iliac lesions and short stenoses
within the femoropopliteal artery catheter mediated treat-
ment has become the gold-standard of care [4]. However,
whilst some success has been reported for subgroups of
patients with aortoiliac disease [5], for many patients with
bilateral, multifocal or long-segment ileofemoral disease
and for patients with additional femoral disease, these
procedures are inappropriate and symptomatic patients
are usually treated by means of surgical bypass of the dis-
ease segment. However, the results of surgical treatement
of AOD as reported in the literature are far from perfect
with major complications reported in 20–25% of cases
including a 10–20% occlusion rate at 5 years and 25–30%
occlusion by 10 years [6-14].
There is also a significant morbidity associated with aor-
tofemoral grafting for occlusive disease as the majority of
patients are arteriopaths with multifocal disease including
cardiovascular and cerebrovascular circulations and are
also frequently smokers leading to additional respiratory
risk factors [15].
The aim of this study was to report the experiences of a
single surgeon in the management of AOD not amenable
to catheter-based therapies including short- and long-
term complications, and patient survival rates.
Methods
All patients undergoing surgery for AOD as a result of crit-
ical ischaemia during the period 1991 to 2004 were iden-
tified from a prospectively maintained vascular surgery
database. Ethical approval for the study was granted by
the institutional review board. Each patient complied
with the definition of critical ischaemia namely: (1) more
than two weeks of recurrent foot pain at rest that requires
regular use of analgesics and is associated with an ankle
systolic pressure of 50 mm Hg or less, or a toe systolic
pressure of 30 mm Hg or less or (2) a non-healing wound
or gangrene of the foot or toes, with similar haemody-
namic measurements [16]. Only patients with confirmed
aortoiliac occlusive disease not amenable to angioplasty
or stenting were included and those with surgical disease
limited to the ileofemoral vascular tree were excluded.
All patients with a chronic presentation who had been
seen in the outpatient department had undergone a care-
ful screening for the presence of cardiovascular risk factors
including: hypertension; diabetes mellitus; hypercholeste-
olaemia; smoking; and a history of cardiovascular/cere-
brovascular disease. In all cases where new risk factors
were identified, appropriate modifications were imple-
mented. Patients with an acute presentation could not
benefit from such an approach. Individuals with ongoing
or past symptoms of cardiovascular/cerebrovascular dis-
ease were assessed by a cardiologist and further investiga-
tions were implemented as indicated.
The vascular assessment included a full examination fol-
lowed by ankle brachial pressure index (ABPI) and Dop-
pler assessment. Angiography was performed to delineate
the extent and distribution of disease. During the course
of the study, this evolved from digital subtraction to mag-
netic resonance angiography.
Prior to operation all patients were reviewed in a multidis-
ciplinary meeting with at least 1 vascular interventional
radiologist at which none of the patients were deemed
suitable for balloon angioplasty or intravascular stenting.
The extent of AOD was classified by a vascular radiologist
in each case. All patients had a minimum 2-year potential
follow-up.
Demographic details, cardiovascular risk factors and fol-
low-up data including postoperative complications were
identified from patient case notes.
All operations were performed by a single surgeon and
followed the same operative technique. The standard
operative procedure consisted of a midline laparotomy
through which the small bowel was retracted allowing
access to the aorta. Having confirmed the preoperative
distribution of disease within the intra-abdominal vascu-
lar tree, the lumen of the aorta was partially occluded
using a Satinsky arterial clamp. An arteriotomy was per-
formed and the proximal end of an appropriately-sized
polyester graft was sutured in place end-to-side. The flowBMC Surgery 2008, 8:19 http://www.biomedcentral.com/1471-2482/8/19
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was then restored whilst dissection of the femoral arteries
continued. The limbs of the graft were then tunnelled
beneath the inguinal ligaments as an anatomical bypass
and anastomosed onto suitable segments of femoral
artery, usually the common femoral. In 28 of 38 bypasses
performed for Type III disease a femoral disobliteration or
profundoplasty was performed and in 6 cases a femoropo-
liteal bypass was constructed during the same anaesthetic.
Post-operatively, all patients were followed in the vascular
outpatient clinic where a clinical assessment was per-
formed with subsequent imaging studies as indicated. Sec-
ondary prevention measures based upon minimising the
cardiovascular risk profile were continued postopera-
tively.
Mortality data was obtained form the hospital patient
information system and verified against CEPOD (confi-
dential enquiry into perioperative deaths) returns and to
death certificate returns to Health Solutions Wales.
A Kaplan-Meier analysis was performed to examine the
survival of patients undergoing surgical bypass using
MedCalc 9.4.2 (® MedCalc, Frank Schoojans, Mariakerke,
Belgium).
Results
During the period of the study, 86 patients (47 males and
39 females) with critical ischaemia underwent aortob-
ifemoral bypass for AOD with a mean patient age was 60
years (SEM: 1 year; range: 40–80). All patients had rest
pain not responding to analgesia and all were classified as
ASA (American Society of Anaesthesiologists) grade II (n
= 39) or III (n = 47). All patients had significant cardiovas-
cular disease and many had a history of respiratory disease
or were smokers as summarised in Table 1.
The most common distribution of AOD was type II (n =
37; 43%) followed by type III (n = 33; 38%) then type I (n
= 16; 19%).
The complications are summarised in Table 2. Early com-
plications, within 12 months of surgery, were noted in 6
cases (7%) and consisted of 4 cases of thrombotic occlu-
sion of a diseased but previously patent superficial femo-
ral artery distal to the graft and 2 cases of fatal peri-
operative haemorrhage. All 4 episodes of thrombosis
occurred in patients with Type III disease in which the
extent of femoropopliteal disease had not been appreci-
ated preoperatively due to the poor inflow. All 4 patients
underwent thrombectomy and distal reconstruction and
no limbs were amputated.
The 2 patient deaths occurred in patients of ASA grade 3
who had been admitted as emergencies with critical
ischaemia and borderline viability as a result of acute
deterioration of their chronically ischaemic limbs. Both
patients suffered significant bleeding following reper-
fusion due to the development of a coagulopathy. This in
turn lead to peri-operative myocardial ischaemia then
subsequent cardiac arrest during the early post-operative
phase.
Late complications, occurring after 12 months, were seen
in 10 of 69 (14%) surviving patients. The complications
consisted of: 3 episodes of graft stenosis, 4 cases of graft
thrombosis; and 3 cases of late graft infection. All 3 epi-
sodes of graft stenosis occurred at the distal anastomosis
and were due to intimal hyperplasia at the anastomotic
site. In each case, balloon angioplasty was successful in
dilating the stenosed segment and surgical exploration
was not required.
In addition 4 patients with no prior history of calf claudi-
cation developed new symptoms. In these 4 cases, investi-
gation revealed progression of disease in distal vessels
despite good quality inflow and patent grafts. Only 1
patient has required an amputation, this being a smoker
with Type III AOD who continued his habit after a good
initial result from surgery and underwent a below knee
amputation 3 years later due to progressive distal disease.
The 30-day mortality was 10.4%, with an actual 1-year
patient and graft survival of 80%. This early mortality
Table 1: Cardiovascular risk factor profiles of patients 
undergoing aortic reconstruction for AOD.






Hypertension 8 (44%) 35 (88%) 23 (82%)
Hypercholesterolaemia 10 (56%) 28 (70%) 19 (67%)
Diabetes Mellitus 1 (6%) 5 (13%) 4 (14%)
Angina 4 (22%) 18 (45%) 13 (46%)
Myocardial Infarct 1 (6%) 7 (18%) 8 (29%)
Transient Ischaemic Attack 0 (0%) 4 (10%) 4 (14%)
Cerebrovascular Accident 0 (0%) 2 (5%) 2 (7%)
Smoking (Current or Ex-smoker) 13 (72%) 34 (85%) 22 (79%)
Respiratory Disease 5 (28%) 15 (38%) 11 (39%)
Table 2: Complications experienced following aortic 
reconstruction for AOD.
Complication Number of Patients (%)
Early 6/86 (7%)
Thrombosis within diseased SFA 4
Fatal haemorrhage 2
Late  10/69 (14%)
Graft stenosis 3
Graft thrombosis 4
Graft infection 3BMC Surgery 2008, 8:19 http://www.biomedcentral.com/1471-2482/8/19
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included: the 2 cases related to haemorrhage already
detailed; 2 of multi-organ failure and 5 related to myocar-
dial infarction. At 2 years follow-up, there were an addi-
tional 6 deaths due to cardiovascular disease but no
further graft losses were identified. If the deaths within 1-
year are excluded the median survival of those patients
who subsequently died during follow-up is 4.65 years.
The survival of patients undergoing bypass is summarised
in Figure 1.
During the overall period of follow-up ranging from 1 to
13 years, 53 of 86 patients died. The causes of death are
summarised in Table 3. The vast majority, 41/53 were car-
diovascular in origin either cardiovascular (n = 35) or cer-
ebrovascular (n = 5).
Discussion
The primary finding of the study was that aortobifemoral
grafting for AOD can be performed with acceptable peri-
operative morbidity and morality, in a group with signifi-
cant comorbidity, and with it providing excellent
symptomatic relief for the vast majority of patients. On
the surface, some aspects of this series may appear inferior
to many of the large published series [6-14], however, a
number of factors need to be considered. All the previous
series, the most recent of which was 1992 describe an era
before catheter based therapies were available or at best
when the technology was not in widespread use. They
therefore include a number of younger and fitter patients
with less extensive cardiovascular and less advanced
peripheral vascular disease which in many cases may have
been amenable to dilatation or stenting. We have had a
full interventional radiology service at our disposal since
the first patient was treated and all vascular patients have
been discussed in a surgical-radiology conference with the
radiological interventionalist prior to surgery. Therefore
numbers were significantly smaller than published series,
patients had more advanced disease at presentation and
consequently had a high risk cardiocvascular profile.
Furthermore, several of the published series provide no or
incomplete data about the disease distribution and sever-
Kaplan-Meier survival curve for patients undergoing aortic reconstruction for AOD Figure 1
Kaplan-Meier survival curve for patients undergoing aortic reconstruction for AOD.BMC Surgery 2008, 8:19 http://www.biomedcentral.com/1471-2482/8/19
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ity, and in many case there is a wide variation in the indi-
cation for operation from moderate claudication to
critical ischaemia. The variation in severity of cardiovascu-
lar disease between this study and other published studies
is typified by the data from the Leiden group which notes
comparable rates of long-term mortality from cardiovas-
cular and malignant causes [14]. In the current series, car-
diovascular causes including cardio- and cerebro-vascular
causes accounted for 74% of deaths indicating that our
patients had more advanced cardiovascular disease.
Interestingly, van den Akker [14] also provided a break-
down of their results according to patient symptoms and
note that results, including patient survival and graft
thrombosis rates, were significantly poorer for patients
with critical ischaemia. This observation was also been
noted by Crawford et al. [12] who reported significantly
worse early (6% versus 3%) and late mortality (55% versus
39%) rates in patients with rest pain when compared with
claudication alone. When this is taken into consideration,
together with the fact that many the Houston patients
may have been suitable for angioplasty then the 10.4%
30-day mortality in our series appears far more accepta-
ble.
A further interesting observation was the fact that the dis-
tribution of disease in the current study was significantly
different to that reported by other centers. Whilst Brewster
and Darling [9] reported relative percentages for Types I-
III of 13:21:66, with a significantly higher proportion of
Type III, Szilagyi and colleagues [13] noted the opposite
with a ratio of 65:21:14. Patients with Type II and III dis-
ease have a higher prevalence of: diabetes; hypertension;
cardio- and cerebrovascular disease, and so it is not sur-
prising that these patients have a poorer outcome in rela-
tion to mortality and disease recurrence/progression[15].
Interestingly for the cohort surviving a year, there were a
further 6 deaths between 1- and 2-years, however, there
were no additional graft losses in this period. All the
deaths in this group were due to cardiovascular causes
suggesting that aggressive management of cardiovascular
risk factors mat be of significant benefit for this cohort of
patients.
Another surgical alternative for high risk patients with crit-
ical ischaemia would be axillobifemoral grafting [17].
However, when this procedure is performed in high risk
patients with critical ischaemia the results are significantly
worse than for aortobifemoral grafting with mortalities of
up to 18% and graft patencies of 33–85% reported. These
are significantly worse than for axillobifemoral and so the
procedure has limited value for patients fit enough to
undergo aortobifemoral grafting.
A recent article by Upchurch and colleagues examined the
effects of introduction of 'new technology' on manage-
ment of aorto-iliac occlusive disease. During the period
1996 – 2000 they noted an 850% increase in stenting and
a 15.5% reduction in bypass [18] and an overall signifi-
cant increase in the number of procedures performed.
Unfortunately, no data was supplied as to the radiological
distribution and severity of the disease or patient symp-
toms prior to intervention. Furthermore it did not look at
outcomes in terms of complications, recurrent symptoms
or 30-day or longer mortality. Interestingly, the majority
of procedures were performed by radiologists. Whilst in
hospital mortality rates were higher following bypass and
duration of stay longer, it is difficult to directly compare
such results and come up with valid conclusions as to the
role of stenting as there was no means of comparing the 2
populations. To-date no randomized controlled trial has
compared the two modalities. One of the major concerns
addressed by those commenting on the paper were the
training issues with reduced numbers of operations per-
formed and management of vascular disease being drawn
away from surgeons.
There has been considerable debate since the conception
of surgical management for AOD which was recently sum-
marized by Rutherford [19] and include: endarterectomy
versus bypass; aorto-bisiliac versus aorto-bifemoral; end-
to-side versus end-to-end; role of adjunctive profundo-
plasty; staged versus concomitant distal bypass; and
axillo-femoral versus aaorto-bifemoral. In the authors
experience almost all cases require bypass rather than sim-
ply endarterectomy with end-to-side proximal and bifem-
oral distal anastomoses with profundoplasty performed
on an as required basis. This reduces the duration of the
operation and hence the ischaemic time so limiting the
potential ischaemia-reperfusion injury. Femoropopliteal
bypass is only performed in selected basis at the primary
operation or if there is no run off and axillofemoral grafts
are limited to extremely high risk patients or those with
hostile abdomens.
Table 3: Causes of death following aortic reconstruction for 
AOD.
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More recently, other options have been reported which
may take over the mantle from the traditional open aor-
tofemoral bypass including: hand-assisted laparoscopic
[20]; totally laparoscopic [21]; robot-assisted bypass [22]
and endografting [23]. Each method has its proponents
who report potential benefits over open surgery but none
have so far been compared in the setting of a randomized
controlled trial. At present, although indications are
fewer, aortofemoral bypass remains the gold-standard
operation for patients with significant symptoms from
AOD that is not amenable to catheter-based treatment.
Conclusion
Aortic reconstruction provides long-standing sympto-
matic relief for the majority of patients with extensive
aorto-occlussive disease for whom stenting is not feasible.
However, the continued atrition in patient survival
beyond the first postoperative year due to co-existent car-
diovascular disease suggests that comprehensive cardio-
vascular risk factor management is required in these
patients.
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